Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion.

In November 2002, he presented a swelling with oedema and pain on the left distal tibia, the MRI showed a lytic bone lesion with cortical destruction. An open biopsy was positive for melanoma. After a PET-computed tomography (CT) scan excluded disease elsewhere (Fig. 1a), we performed a hyperthermic limb perfusion (HLP) with melphalan 100 mg and TNF 1 mg. In May 2003, the patient was started on high-dose IFN because of persistence of the osteolytic lesion at the standard radiographic examination. In May 2004, the contrast MRI showed a tibial fracture, which obliged the patient to walk only with the aid of crutches. With the aim of improving bone recalcification we started zoledronic acid (ZA). A new PET/CT in January 2005 showed a complete resolution of the fracture without any fluorodeoxyglucose uptake; the complete healing of the lesion was confirmed also by a contrast MRI performed in February 2005. The ZA was nevertheless continued till March 2006. The complete response persisted at the last radiograph and PET/CT scan, performed in September 2007 (Fig.1b). As of July 2008, the patient is still free from recurrence, walking normally and working full time.

[1]  R. Greil,et al.  Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. , 2008 .

[2]  M. Caraglia,et al.  Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.

[3]  Rong-Sen Yang,et al.  Rare clinical experiences for surgical treatment of melanoma with osseous metastases in Taiwan , 2007, BMC musculoskeletal disorders.

[4]  R. Essner,et al.  The role of surgery in treatment of stage IV melanoma , 2006, Journal of surgical oncology.

[5]  J. Marsden,et al.  Palliation of skeletal melanoma metastases with isolated limb perfusion chemotherapy. , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[6]  J. Mckinnon Palliation by perfusion: Is it worth it? , 2005, Journal of surgical oncology.

[7]  A. Eggermont,et al.  Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients , 2005, Journal of surgical oncology.

[8]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[9]  C. Riebeling,et al.  Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells , 2004, British Journal of Cancer.

[10]  A. Eggermont,et al.  Prognostic factors for survival after isolated limb perfusion for malignant melanoma. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  G. Bieler,et al.  Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death , 2003, Journal of Biological Chemistry.

[12]  G. Avvisati,et al.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  L. Devy,et al.  Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid , 2002, Journal of Pharmacology and Experimental Therapeutics.

[14]  R. Mirimanoff,et al.  Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  A. V. van Geel,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  C. Perez,et al.  Bone metastasis: review and critical analysis of random allocation trials of local field treatment. , 1999, International journal of radiation oncology, biology, physics.

[17]  H. Schwartz,et al.  Heterogeneous Survival Rates for Isolated Skeletal Metastases From Melanoma , 1996, Clinical orthopaedics and related research.

[18]  I. Tannock,et al.  Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Avilés,et al.  Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma , 2007, Medical oncology.